

Eugeen Vanmechelen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6925112/publications.pdf>

Version: 2024-02-01

119
papers

13,357
citations

20817

60
h-index

22166

113
g-index

126
all docs

126
docs citations

126
times ranked

9722
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal Fluid β -Amyloid(1-42) in Alzheimer Disease. Archives of Neurology, 1999, 56, 673.	4.5	594
2	Evaluation of CSF-tau and CSF-A β 242 as Diagnostic Markers for Alzheimer Disease in Clinical Practice. Archives of Neurology, 2001, 58, 373-9.	4.5	487
3	Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme-Linked Immunosorbent Assay. Journal of Neurochemistry, 1993, 61, 1828-1834.	3.9	474
4	Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neuroscience Letters, 2000, 285, 49-52.	2.1	452
5	Tau and A β 242 in Cerebrospinal Fluid from Healthy Adults 21-93 Years of Age: Establishment of Reference Values. Clinical Chemistry, 2001, 47, 1776-1781.	3.2	420
6	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Archives of Neurology, 2010, 67, 949.	4.5	407
7	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. Archives of Neurology, 2012, 69, 1445.	4.5	407
8	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neuroscience Letters, 2001, 297, 187-190.	2.1	401
9	Simultaneous Measurement of β -Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology. Clinical Chemistry, 2005, 51, 336-345.	3.2	400
10	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease. Archives of General Psychiatry, 2004, 61, 95.	12.3	390
11	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	2.4	348
12	The β -Secretase BACE1 in Alzheimer's Disease. Biological Psychiatry, 2021, 89, 745-756.	1.3	336
13	Standardization of measurement of β -amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 245-258.	3.0	286
14	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	7.7	285
15	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	1.4	280
16	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Review of Proteomics, 2008, 5, 207-224.	3.0	242
17	Evaluation of plasma A β 40 and A β 242 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 357-367.	3.1	242
18	Cerebrospinal fluid tau and A β 242 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neuroscience Letters, 1999, 273, 5-8.	2.1	239

#	ARTICLE	IF	CITATIONS
19	CSF Total tau, A β 242 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2001, 24, 087-098.	4.0	232
20	CSF levels of tau, β -amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. <i>Journal of Neural Transmission</i> , 2000, 107, 563-579.	2.8	227
21	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , 2008, 29, 1143-1159.	3.1	217
22	Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. <i>Molecular Psychiatry</i> , 2003, 8, 343-347.	7.9	209
23	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A β pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	6.9	202
24	Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. <i>Journal of Neurochemistry</i> , 2003, 85, 1581-1591.	3.9	196
25	Cerebrospinal fluid β -synuclein in neurodegenerative disorders: A marker of synapse loss?. <i>Neuroscience Letters</i> , 2009, 450, 332-335.	2.1	194
26	Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke. <i>Journal of Alzheimer's Disease</i> , 2000, 2, 199-206.	2.6	183
27	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. <i>Brain Research</i> , 2010, 1362, 13-22.	2.2	180
28	Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 15, 169-176.	1.5	170
29	Analytical performance and clinical utility of the INNOTEST β PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1472-80.	2.3	145
30	Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. <i>Annals of Neurology</i> , 2005, 58, 748-757.	5.3	144
31	Cerebrospinal fluid levels of total-tau, phospho-tau and A β 242 predicts development of Alzheimer's disease in patients with mild cognitive impairment. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 47-51.	2.1	140
32	Nonfibrillar diffuse amyloid deposition due to a gamma42-secretase site mutation points to an essential role for N-truncated Abeta42 in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2000, 9, 2589-2598.	2.9	135
33	Decreased CSF- β -Amyloid 42 in Alzheimer's Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β -Amyloid Induced by Disparate Mechanisms. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 13, 112-118.	1.5	125
34	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775.	0.8	122
35	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 255-260.	2.6	117
36	Terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1461-1469.	0.8	117

#	ARTICLE	IF	CITATIONS
37	No association of CSF biomarkers with APOE ϵ 4, plaque and tangle burden in definite Alzheimer's disease. <i>Brain</i> , 2007, 130, 2320-2326.	7.6	110
38	Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1119-1128.	2.6	110
39	Plasma Levels of β -Amyloid(1-40), β -Amyloid(1-42), and Total β -Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins. <i>Archives of Neurology</i> , 2004, 61, 333.	4.5	109
40	The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer's Disease, Reflecting a Common Pathophysiological Process. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 257-264.	1.5	102
41	Identification of Novel β -Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. <i>Neurochemical Research</i> , 2011, 36, 2029-2042.	3.3	99
42	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. <i>Neurobiology of Aging</i> , 2008, 29, 812-818.	3.1	94
43	Identification of two-dimensionally separated human cerebrospinal fluid proteins by N-terminal sequencing, matrix-assisted laser desorption/ionization mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometry, and tandem mass spectrometry. <i>Electrophoresis</i> , 2000, 21, 2266-2283.	2.4	91
44	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1141-1154.	0.8	89
45	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 198.	6.2	87
46	The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 256-265.	1.5	86
47	The utility of β -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. <i>Biomarkers in Medicine</i> , 2016, 10, 19-34.	1.4	86
48	Aberrant Splicing in the Presenilin-1 Intron 4 Mutation Causes Presenile Alzheimer's Disease by Increased A β 42 Secretion. <i>Human Molecular Genetics</i> , 1999, 8, 1529-1540.	2.9	84
49	Tau as a biomarker of neurodegenerative diseases. <i>Biomarkers in Medicine</i> , 2008, 2, 363-384.	1.4	83
50	Amino-Truncated β -Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment. <i>Clinical Chemistry</i> , 2005, 51, 1650-1660.	3.2	82
51	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. <i>Neurobiology of Disease</i> , 2005, 20, 625-637.	4.4	82
52	Cerebrospinal beta-amyloid (β 42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. <i>Neuroscience Letters</i> , 2000, 284, 85-88.	2.1	81
53	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 871-882.	3.7	79
54	Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry. <i>Journal of Proteome Research</i> , 2008, 7, 2114-2120.	3.7	74

#	ARTICLE	IF	CITATIONS
55	Low cerebrospinal fluid β -amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. <i>Neuroscience Letters</i> , 2001, 314, 33-36.	2.1	71
56	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. <i>BMC Neurology</i> , 2017, 17, 170.	1.8	70
57	Increased CSF α -synuclein levels in Alzheimer's disease: Correlation with tau levels. <i>Alzheimer's and Dementia</i> , 2014, 10, S290-8.	0.8	69
58	An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor- α . <i>Neurochemistry International</i> , 2001, 38, 557-565.	3.8	68
59	CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. <i>Brain Research Bulletin</i> , 2003, 61, 235-242.	3.0	68
60	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	6.1	65
61	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , 2010, 31, 1867-1876.	3.1	63
62	Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples. <i>Analytica Chimica Acta</i> , 2018, 1015, 74-81.	5.4	60
63	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , 2021, 97, e1681-e1694.	1.1	60
64	Relevance of $A\beta_{42}/40$ Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 138.	3.4	59
65	Postmortem changes in the phosphorylation state of tau-protein in the rat brain. <i>Neurobiology of Aging</i> , 1998, 19, 535-543.	3.1	57
66	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2003, 72, 520-526.	2.9	55
67	Monitoring of β -Amyloid Dynamics after Human Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2014, 31, 42-55.	3.4	54
68	Evolution of $A\beta_{42}$ and $A\beta_{40}$ levels and $A\beta_{42}/A\beta_{40}$ ratio in plasma during progression of Alzheimer's disease: A multicenter assessment. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 205-208.	3.3	52
69	Cerebrospinal fluid τ , and β -amyloid(1-42) in dementia disorders. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 2005-2011.	4.6	50
70	Assessing the commutability of reference material formats for the harmonization of amyloid- β measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1177-1191.	2.3	49
71	The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?. <i>Acta Neuropathologica Communications</i> , 2019, 7, 31.	5.2	49
72	Evidence That $A\beta_{42}$ Plasma Levels in Presenilin-1 Mutation Carriers Do not Allow for Prediction of Their Clinical Phenotype. <i>Neurobiology of Disease</i> , 1999, 6, 280-287.	4.4	48

#	ARTICLE	IF	CITATIONS
73	Evaluation of Plasma A β ² as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 231-238.	2.6	48
74	The Glu318Gly Substitution in Presenilin 1 Is Not Causally Related to Alzheimer Disease. <i>American Journal of Human Genetics</i> , 1999, 64, 290-292.	6.2	47
75	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1523-1538.	2.6	46
76	Plasma p τ ₂₃₁ , p τ ₁₈₁ , τ -PET Biomarkers, and Cognitive Change in Older Adults. <i>Annals of Neurology</i> , 2022, 91, 548-560.	5.3	42
77	Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 117-131.	2.6	40
78	Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation. <i>Neuroscience Letters</i> , 1996, 220, 9-12.	2.1	37
79	TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. <i>Acta Neuropathologica Communications</i> , 2015, 3, 15.	5.2	37
80	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937.	3.2	37
81	Generation and characterization of mouse microglial cell lines. <i>Journal of Neuroimmunology</i> , 1994, 52, 153-164.	2.3	35
82	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. <i>EBioMedicine</i> , 2022, 76, 103837.	6.1	34
83	τ Immunoreactivity Detected in Human Plasma, But No Obvious Increase in Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 442-445.	1.5	31
84	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	3.1	30
85	Developmental expression of tau proteins in the chicken and rat brain: Rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. <i>International Journal of Developmental Neuroscience</i> , 1995, 13, 607-617.	1.6	29
86	Analytical aspects of molecular Alzheimer's disease biomarkers. <i>Biomarkers in Medicine</i> , 2012, 6, 377-389.	1.4	26
87	Brain A β load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019, 15, 1274-1285.	0.8	25
88	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 65.	6.2	25
89	Association of CSF apolipoprotein E, A β ⁴² and cognition in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2002, 23, 205-211.	3.1	24
90	Cerebrospinal fluid neurogranin site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 617-627.	3.7	24

#	ARTICLE	IF	CITATIONS
91	Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. <i>Leukemia</i> , 2000, 14, 2076-2084.	7.2	23
92	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 318-331.	3.2	22
93	Tau Monoclonal Antibody Generation Based on Humanized Yeast Models. <i>Journal of Biological Chemistry</i> , 2015, 290, 4059-4074.	3.4	21
94	Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 277-289.	1.3	20
95	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 88.	6.2	20
96	Association of Plasma A β 40 Peptides, But Not A β 42, with Coronary Artery Disease and Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 161-169.	2.6	18
97	Validation of soluble amyloid β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2016, 137, 112-121.	3.9	17
98	Unaltered Plasma Levels of A β -Amyloid and A β -Amyloid upon Stimulation of Human Platelets. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 93-97.	1.5	16
99	Neurotoxicity Marker Profiles in the CSF are not Age-Dependent but Show Variation in Children Treated for Acute Lymphoblastic Leukemia. <i>NeuroToxicology</i> , 2004, 25, 471-480.	3.0	16
100	A β -Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130.	6.2	16
101	Potential sources of interference on A β immunoassays in biological samples. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 39.	6.2	14
102	Functional Mannose-Binding Lectin Haplotype Variants are Associated with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 121-127.	2.6	12
103	Phospho-specific plasma τ 181 assay detects clinical as well as asymptomatic Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 734-746.	3.7	11
104	A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7221.	4.1	11
105	Plasma A β -secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021, 17, 629-640.	0.8	10
106	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2019, 497, 204-211.	1.1	9
107	BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 313-322.	2.6	9
108	Critical Steps to be Taken into Consideration Before Quantification of A β -Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. <i>Neurology and Therapy</i> , 2019, 8, 129-145.	3.2	8

#	ARTICLE	IF	CITATIONS
109	A First Tetraplex Assay for the Simultaneous Quantification of Total $\hat{\tau}$ -Synuclein, Tau, $\hat{\tau}$ ² -Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. PLoS ONE, 2016, 11, e0153564.	2.5	6
110	A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. Frontiers in Molecular Biosciences, 2020, 7, 48.	3.5	5
111	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. Alzheimer's Research and Therapy, 2022, 14, .	6.2	5
112	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. Neurobiology of Aging, 2020, 88, 83-90.	3.1	4
113	Tau as a molecular biomarker in cerebrospinal fluid and plasma. Neurobiology of Aging, 2014, 35, S23.	3.1	1
114	P4-232: A monoclonal antibody-based elisa for neurogranin. , 2015, 11, P869-P869.		1
115	CSF Markers for Early Alzheimer's Disease. , 0, , 275-283.		0
116	P2-127: TDP-43 AS A BIOMARKER FOR FRONTOTEMPORAL LOBE DEGENERATION: A SYSTEMATIC REVIEW OF EXISTING ANTIBODIES. , 2014, 10, P517-P518.		0
117	P1â€251: CSFâ€NEUROGRANIN, BUT NOT BACE1, IS AN ALZHEIMER'S DISEASE SPECIFIC BIOMARKER. Alzheimer's and Dementia, 2018, 14, P376.	0.8	0
118	Exploring molecular biomarkers with potential prognostic value in longitudinal observational studies on Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e047017.	0.8	0
119	Cerebrospinal fluid neurogranin in Alzheimerâ€™s disease studies: are immunoassay results interchangeable?. Clinical Chemistry and Laboratory Medicine, 2021, 60, e13-e17.	2.3	0